Assessing the Increased Deal-Making Activity & Market Size Opportunity for Bispecifics & Engagers
- Reviewing differences in bispecific modalities including dual inhibitors, agonists, T-cell and other immune-cell engagers
- How are novel targets and formats expanding engager pipelines across both blood and solid tumors?
- What does this mean for the potential first-in-class engager approvals?
- How can engagers and bispecifics be complementary to other drug modalities to improve patient outcomes?